Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies

被引:34
作者
Shan, Shan [1 ]
She, Jun [2 ]
xue, Zhi-qiang [3 ]
Su, Chun-xia [4 ]
Ren, Shen-xiang [4 ]
Wu, Feng-ying [4 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Respirol, Shanghai Peoples Hosp 6, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China
[3] Peoples Liberat Army Gen Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[4] Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
来源
PLOS ONE | 2017年 / 12卷 / 09期
基金
中国国家自然科学基金;
关键词
RISK; SINGLE; NEOPLASMS; AGE;
D O I
10.1371/journal.pone.0185485
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives To investigate the characteristics and survival of lung cancer patients with additional malignant primary cancers. Methods Records of lung cancer patients newly diagnosed in Shanghai Pulmonary Hospital between January 2000 and January 2010 were retrospectively reviewed. Patients with second primary lung cancer and those with lung cancer only were included for detailed analysis. Results Of 27642 newly diagnosed lung cancer patients, 283 patients (1.02%) suffered previous additional primary cancers. Compared with single primary lung cancer, patients with secondary lung cancer associated other primary cancers were more often women (female to male ratio 1:1.72 vs 1:2.58, P = 0.018), older (64.2 vs 60.5 years old, P<0.001), more squamous cell type (30.7% vs 20.5%, P = 0.004), less small cell (3.9% vs 15.5%, P<0.001) type, at earlier stages (17.7% vs 11.0% for stage I, P = 0.014), and more frequently with family history of cancers (7.8% vs 3.9%, P = 0.038). The most common previous primary cancers observed were colorectal (22.0%), breast (18.4%), gastric (14.4%) and larynx cancers (11.9%). Approximately 42.9% of patients were diagnosed with lung cancer 2 to 6 years after diagnosis of initial primary cancers. The survival of patients with secondary lung cancer associated other malignancies was not significantly different from those with single lung cancer (P = 0.491), while synchronous multiple primary malignancies showed worse prognosis compared with those with metachronous ones or single lung cancer (p = 0.012). Conclusion The possibility of second primary lung cancer should always be considered during the follow-up of related cancer types, especially those with family history of cancers. secondary lung cancer associated other primary malignancies have non-inferior survival than those with single lung cancer.
引用
收藏
页数:11
相关论文
共 28 条
  • [21] Multiple primary tumours: Incidence estimation in the presence of competing risks
    Rosso S.
    Terracini L.
    Ricceri F.
    Zanetti R.
    [J]. Population Health Metrics, 7 (1)
  • [22] Multiple tumours in survival estimates
    Rosso, Stefano
    De Angelis, Roberta
    Ciccolallo, Laura
    Carrani, Eugenio
    Soerjomataram, Isabelle
    Grande, Enrico
    Zigon, Giulia
    Brenner, Hermann
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (06) : 1080 - 1094
  • [23] Lung Cancer in China Challenges and Interventions
    She, Jun
    Yang, Ping
    Hong, Qunying
    Bai, Chunxue
    [J]. CHEST, 2013, 143 (04) : 1117 - 1126
  • [24] Cancer Statistics, 2014
    Siegel, Rebecca
    Ma, Jiemin
    Zou, Zhaohui
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (01) : 9 - 29
  • [25] Soerjomataram Isabelle, 2009, V471, P85, DOI 10.1007/978-1-59745-416-2_5
  • [26] Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment
    Swerdlow, AJ
    Barber, JA
    Hudson, GV
    Cunningham, D
    Gupta, RK
    Hancock, BW
    Horwich, A
    Lister, TA
    Linch, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 498 - 509
  • [27] RISK OF 2ND CANCERS AFTER TREATMENT FOR HODGKINS-DISEASE
    TUCKER, MA
    COLEMAN, CN
    COX, RS
    VARGHESE, A
    ROSENBERG, SA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (02) : 76 - 81
  • [28] WATANABE S, 1984, JNCI-J NATL CANCER I, V72, P1021